High dose rhenium-186-labeling of monoclonal antibodies for clinical application pitfalls and solutions

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2360-2370

  Van Gog, Frank B ^a   Visser, Gerard W M ^b   Stroomer, Joep W G ^a   Roos, Jan C ^a   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

186Re labeling kit; 186Re labeled monoclonal antibody; 99mTc labeled monoclonal antibody; Head and neck cancer; Radioimmnoscintigraphy; Radioimmunotheraphy

Indexed keywords

MERTIATIDE TC 99M; MONOCLONAL ANTIBODY; RHENIUM 186;

ANTIBODY DETECTION; CONFERENCE PAPER; DOSIMETRY; DRUG MEGADOSE; HEAD AND NECK CANCER; HUMAN; IMAGE ENHANCEMENT; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA;

EID: 0031444654     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2360::aid-cncr5>3.0.co;2-f     Document Type: Conference Paper

References (24)

1. Van Dongen GAMS, Brakenhoff RH, De Bree R, Gerretsen M, Quak JJ, Snow GB. Progress in radioimmunotherapy of head and neck cancer. Oncol Rep 1994;1:259-64.
2. Quak JJ Van Dongen GAMS, Balm AJM, Brakkee JPG, Scheper RJ, Snow GB, et al. A 22 kDa surface antigen detected by monoclonal antibody E48 is exclusively expressed in stratified squamous and transitional epithelia. Am J Pathol 1990;136:191-7.
3. Schrijvers AHGJ, Quak JJ, Uyterlinde AM, Van Walsum M, Meijer CJLM, Snow GB, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383-90.
4. Brakenhoff RH, Gerretsen M, Knippels EMC, Van Dijk M, Van Essen H, Olde Weghuis D, et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol 1995;129:1677-89.
5. Van Hal NLW, Van Dongen GAMS, Rood-Knippels EMC, Van der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int J Cancer. 1996;1:520-7.
6. De Bree R, Roos JC, Quak JJ, Den Hollander W, Wilhelm AJ, Snow GB, et al. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab′)2 in patients with head and neck cancer. Clin Cancer Res 1995;1:277-86.
7. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995;1:591-8.
8. Coursey BM, Cessna J, Garcia-Torano E. The standardization and decay scheme of rhenium-186. Int J Radiat Appl Instrum Part A 1991;42:865-9.
9. Griffiths GL, Goldenberg DM, Knapp FF, Callahan AP, Chang CH, Hansen HJ. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy labeling and animal biodistribution studies. Cancer Res 1991;51:4594-602.
10. Griffiths GL, Goldenberg DM, Diril H, Hansen HJ. Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer 1994;73:761-8.
11. John E, Thakur ML, DeFulvio J, McDevitt MR, Damjanov I. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation. J Nucl Med 1993;34:260-7.
12. 4 chelate in vitro and in vivo using tumor-bearing nude mice. Nucl Med Biol 1992;19:205-12.
13. Ram S, Buchsbaum DJ. A peptide-based bifunctional chelating agent for Tc-99m-and Re-186 labeling of monoclonal antibodies. Cancer 1994;73:769-73.
14. Goldrosen MH, Biddle WC, Pancook J, Bakshi S, Vanderheyden JL, Fritzberg AR, et al. Biodistribution, pharmacokinetic and imaging studies with Re-186-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice. Cancer Res 1990;50:7973-8.
15. 3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993;34:1953-63.
16. 3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med 1996;37:352-62.
17. Breitz HB, Weiden PL, Vanderheyden JL, Appelbaum JW, Bjorn MJ, Fer MF, et al. Clinical experience with rhenium-186 labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med 1992;33:1099-112.
18. Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ, et al. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med 1993;34:908-17.
19. Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, et al. A phase I trial of rhenium-186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 1993;82:586-93.
20. Haisma HJ, Hilgers J, Zurawski VR. Iodination of monoclonal antibodies for diagnosis and therapy using a convenient one vial method. J Nucl Med 1986;27:1890-5.
21. Quak JJ, Schrijvers AHGJ, Brakkee JGP, Davis HD, Scheper RJ, Balm AJM, et al. Expression and characterization of two differentiation antigens in stratified squamous epithelia and carcinomas. Int J Cancer 1992;50:507-23.
22. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding to infinite antigen excess. J Immunol Methods 1984;72:77-8.
23. 186Re-labeled monoclonal antibody E48 IgG mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 1993;53: 3524-9.
24. 186Re-labeled monoclonal antibody E48. Cell Biophys 1994;24:135-42.